Hello experts/colleagues!

I am currently facing a dosage optimization problem when designing a long-term intervention experiment with GlyRS-IN-1 (Cat.NO.: HY-108940, bought from MCE) in diabetic mice.

I hope to ask the following based on my experience in the field:

Experimental background:

GlyRS-IN-1 is planned to be administered by gavage to construct/intervene a diabetic model (specifically ______, such as STZ-induced/spontaneous type 2 diabetic mice, strain ______, weight range ______g), with an intervention period of 8 weeks, gavage 3 times a week (interval recommendation? Such as every other day/fixed week 1/3/5).

Supplementary explanation:

The specific dosage guide for direct gavage of this compound in the diabetic model has not been retrieved yet. ______ was observed in the preliminary experiment (if there is preliminary data, it can be supplemented, such as reduced activity in the high-dose group).

If there are relevant pharmacokinetic (DMPK) data, dosage regimens for drugs of the same target, or precautions for long-term gavage operations, please share your experience or literature clues!

Looking forward to your reply, thank you!